Francesco Pistelli1, Ferruccio Aquilini1, Fabio Falaschi2, Donella Puliti3, Cristina Ocello3, Andrea Lopes Pegna4, Francesca Maria Carozzi5, Giulia Picozzi6, Marco Zappa3, Mario Mascalchi7, Eugenio Paci3, Laura Carrozzi1,8. 1. Pulmonary Unit, Cardiothoracic and Vascular Department, University Hospital of Pisa, Pisa, Italy. 2. 2nd Radiodiagnostic Unit, Department of Diagnostic Imaging, University Hospital of Pisa, Pisa, Italy. 3. Clinical Epidemiology Unit, Oncological Network, Prevention and Research Institute (ISPRO), Florence, Italy. 4. Formerly Pneumonology Department, University Hospital Careggi, Florence, Italy. 5. Cancer Prevention Regional Laboratory, Oncological Network, Prevention and Research Institute (ISPRO), Florence, Italy. 6. Clinical Breast Unit, Oncological Network, Prevention and Research Institute (ISPRO), Florence, Italy, Florence, Italy. 7. Formerly Clinical Epidemiology Unit, Oncological Network, Prevention and Research Institute (ISPRO), Florence, Italy. 8. Department of Surgical, Medical, and Molecular Pathology and Critical Care Medicine, University of Pisa.
Abstract
BACKGROUND: Changes in smoking habits and predictors of smoking cessation were examined in the randomized ITALUNG lung cancer screening trial. METHODS: In three centers, eligible smokers or ex-smokers (55-69 years, ≥20 pack-years in the last 10 years) were randomized to receive annual invitation for low-dose computed tomography for 4 years or usual care. At invitation, subjects received written information for a free smoking cessation program. Quitting outcome was assessed at year 4. RESULTS: Among participants who completed baseline assessments and year 4 screening, higher quitting (20.8% vs. 16.7%, p = .029) and lower relapse (6.41% vs. 7.56%, p = .50) rates were observed in the active screening group as compared to the usual-care control group. Corresponding figures in the intention-to-treat analysis were as follows: 16.04% versus 14.64% (p = .059) and 4.88% versus 6.43% (p = .26). Quitting smoking was significantly associated to male gender, lower pack-years, and having pulmonary nodules at baseline. Center-specific analyses showed a threefold statistically significant higher probability to quit associated with participating in the smoking cessation program. A subsample of smokers of the scan group from one center showed higher quitting rates over 12-month follow-up as compared to matched controls from the general population who underwent the same smoking cessation program. CONCLUSIONS: Consistently with previous reports, in the ITALUNG trial, screened subjects showed significantly higher quit rates than controls, and higher quit rates were associated with both the presence of pulmonary nodules and participating in a smoking cessation program. Maximal effect on quitting outcome was observed with the participation in the smoking cessation program. IMPLICATIONS: Participating in lung cancer screening promotes smoking cessation. An effective "teachable moment" may be achieved when the smoking cessation intervention is structured as integral part of the screening clinical visits and conducted by a dedicated team of health care professionals. Standardized guidelines for smoking cessation interventions in lung cancer screening are needed.
RCT Entities:
BACKGROUND: Changes in smoking habits and predictors of smoking cessation were examined in the randomized ITALUNG lung cancer screening trial. METHODS: In three centers, eligible smokers or ex-smokers (55-69 years, ≥20 pack-years in the last 10 years) were randomized to receive annual invitation for low-dose computed tomography for 4 years or usual care. At invitation, subjects received written information for a free smoking cessation program. Quitting outcome was assessed at year 4. RESULTS: Among participants who completed baseline assessments and year 4 screening, higher quitting (20.8% vs. 16.7%, p = .029) and lower relapse (6.41% vs. 7.56%, p = .50) rates were observed in the active screening group as compared to the usual-care control group. Corresponding figures in the intention-to-treat analysis were as follows: 16.04% versus 14.64% (p = .059) and 4.88% versus 6.43% (p = .26). Quitting smoking was significantly associated to male gender, lower pack-years, and having pulmonary nodules at baseline. Center-specific analyses showed a threefold statistically significant higher probability to quit associated with participating in the smoking cessation program. A subsample of smokers of the scan group from one center showed higher quitting rates over 12-month follow-up as compared to matched controls from the general population who underwent the same smoking cessation program. CONCLUSIONS: Consistently with previous reports, in the ITALUNG trial, screened subjects showed significantly higher quit rates than controls, and higher quit rates were associated with both the presence of pulmonary nodules and participating in a smoking cessation program. Maximal effect on quitting outcome was observed with the participation in the smoking cessation program. IMPLICATIONS: Participating in lung cancer screening promotes smoking cessation. An effective "teachable moment" may be achieved when the smoking cessation intervention is structured as integral part of the screening clinical visits and conducted by a dedicated team of health care professionals. Standardized guidelines for smoking cessation interventions in lung cancer screening are needed.
Authors: Randi M Williams; Marisa Cordon; Ellie Eyestone; Laney Smith; George Luta; Brady J McKee; Shawn M Regis; David B Abrams; Raymond S Niaura; Cassandra A Stanton; Vicky Parikh; Kathryn L Taylor Journal: Cancer Date: 2022-02-10 Impact factor: 6.921
Authors: Rachel Kohn; Anil Vachani; Dylan Small; Alisa J Stephens-Shields; Dorothy Sheu; Vanessa L Madden; Brian A Bayes; Marzana Chowdhury; Sadie Friday; Jannie Kim; Michael K Gould; Mohamed H Ismail; Beth Creekmur; Matthew A Facktor; Charlotte Collins; Kristina K Blessing; Christine M Neslund-Dudas; Michael J Simoff; Elizabeth R Alleman; Leonard H Epstein; Michael A Horst; Michael E Scott; Kevin G Volpp; Scott D Halpern; Joanna L Hart Journal: Ann Am Thorac Soc Date: 2022-02
Authors: Sara C Buttery; Parris Williams; Rebecca Mweseli; Keir Elmslie James Philip; Ahmed Sadaka; Emily Jade Bartlett; Anand Devaraj; Samual Kemp; Jamie Addis; Jane Derbyshire; Michelle Chen; Katie Morris; Anthony Laverty; Nicholas S Hopkinson Journal: BMJ Open Respir Res Date: 2022-02
Authors: Ankita Ghatak; Sean Gilman; Siobhan Carney; Anne V Gonzalez; Andrea Benedetti; Nicole Ezer Journal: Can Respir J Date: 2022-04-21 Impact factor: 2.130
Authors: Samantha Groves; Grace McCutchan; Samantha L Quaife; Rachael L Murray; Jamie S Ostroff; Kate Brain; Philip A J Crosbie; Janelle Yorke; David Baldwin; John K Field; Lorna McWilliams Journal: Health Expect Date: 2022-05-05 Impact factor: 3.318
Authors: Peter J Mazzone; Gerard A Silvestri; Lesley H Souter; Tanner J Caverly; Jeffrey P Kanne; Hormuzd A Katki; Renda Soylemez Wiener; Frank C Detterbeck Journal: Chest Date: 2021-07-13 Impact factor: 9.410
Authors: Peter J Mazzone; Gerard A Silvestri; Lesley H Souter; Tanner J Caverly; Jeffrey P Kanne; Hormuzd A Katki; Renda Soylemez Wiener; Frank C Detterbeck Journal: Chest Date: 2021-07-13 Impact factor: 9.410